Back to discover
Disease

Esophageal Squamous Cell Carcinoma

Late-stage therapeutic developmentEmerging research
MeSHEsophageal Squamous Cell Carcinoma
2
Publications
23
Clinical trials
1
Related conditions
2021
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Approval: Hetronifly (EMA)

Regulatory2025-02-03EMA

Approval: Loqtorzi (EMA)

Regulatory2024-09-19EMA

Approval: Tevimbra (EMA)

Regulatory2023-09-15EMA

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

Research2021-09-01JAMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 clinical trials expected to report results, the earliest in Q2 2028.
Upcoming Milestones
Clinical Milestones6View
Results posted 2
Results expected 3
Recently completed 1
Activity timeline6

Clinical trials

15 sponsors · 2 new · 1 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
23
All trials
6
Active
12
Late-stage
6
Completed
Late-stage studies

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Phase 3 · Recruiting · Daiichi Sankyo

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II Clinical Study

Phase 2/3 · Recruiting · Peking Union Medical College Hospital

A Randomized, Open-Label, Multicenter Phase III Study of QLC5508 Versus Investigator's Choice Chemotherapy in Pretreated Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Phase 3 · Recruiting · Qilu Pharmaceutical Co., Ltd.

The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma

Phase 2/3 · Recruiting · Qingdao Central Hospital

A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 · Recruiting · Beijing Konruns Pharmaceutical Co., Ltd.

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma.

Phase 3 · Completed · Merck Sharp & Dohme LLC
Recruiting

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Phase 3 · Recruiting · Daiichi Sankyo

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II Clinical Study

Phase 2/3 · Recruiting · Peking Union Medical College Hospital

A Randomized, Open-Label, Multicenter Phase III Study of QLC5508 Versus Investigator's Choice Chemotherapy in Pretreated Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Phase 3 · Recruiting · Qilu Pharmaceutical Co., Ltd.

The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma

Phase 2/3 · Recruiting · Qingdao Central Hospital

A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 · Recruiting · Beijing Konruns Pharmaceutical Co., Ltd.

An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab Plus Chemotherapy in a First-Line Setting for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in US Racial and Ethnic Minority Patients

Phase 2 · Recruiting · BeOne Medicines
Recently completed

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma.

Phase 3 · Completed · Merck Sharp & Dohme LLC

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma

Phase 3 · Completed · BeiGene

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1001 in Combination With Fluorouracil and Cisplatin (FP) Compared to Placebo in Combination With FP as First-Line Therapy in Subjects With Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Phase 3 · Completed · CStone Pharmaceuticals

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase 3 · Completed · BeiGene

A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer

Phase 3 · Completed · Sun Yat-sen University

A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial

Phase 3 · Completed · Fudan University

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20202021
Leading journals2
  • JAMA1
  • Molecular cancer1
Leading researchers8
  • Zhang X2
  • Ba Y1
  • Bai Y1
  • Chen X1
  • Chen Z1
  • Cheng Y1
  • Cui W1
  • Fan Q1
Affiliations (unnormalised)6
  • 900 Hospital of the Joint Logistics Support Force1
  • Affiliated Hospital of Jining Medical University1
  • Anhui Chest Hospital1
  • Army Medical Center of PLA1
  • Cancer Hospital Chinese Academy of Medical Sciences1
  • Chinese Academy of Medical Sciences1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Esophageal Neoplasms2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.

Identifiers
MeSHEsophageal Squamous Cell Carcinoma
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.